Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 7/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839412 | 0.90 | KMT2A (0.51) | SIGMAR1KMT2APRMT6MEN1 | |
| SCHEMBL4844432 | 0.87 | PRMT6 (0.58) | KMT2APRMT6TDP1HRH3 | |
| SCHEMBL4850572 | 0.86 | PRMT6 (0.56) | KMT2APRMT6TDP1HRH3 | |
| SCHEMBL4841024 | 0.84 | NCF1 (0.61) | CXCR4KMT2APRMT6TDP1HRH3 | |
| SCHEMBL4848459 | 0.78 | GRM2 (0.50) | CXCR4SIGMAR1HTR6KMT2AMEN1 | |
| SCHEMBL21799527 | 0.76 | PRMT6 (0.72) | CXCR4SIGMAR1KMT2APRMT6MEN1 | |
| SCHEMBL593143 | 0.76 | SLC6A4 (0.71) | CXCR4SIGMAR1SLC6A4HTR6KMT2A | |
| SCHEMBL21800034 | 0.76 | SIGMAR1 (0.66) | CXCR4SIGMAR1KMT2APRMT6MEN1 | |
| SCHEMBL4847363 | 0.76 | ROCK1 (0.49) | HRH3 | |
| SCHEMBL16830448 | 0.75 | SLC6A4 (0.69) | CXCR4SIGMAR1SLC6A4HTR6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368462-B1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080058423-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058423-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC4R | CXCR4 1631/4885SIGMAR1 281/4885SLC6A4 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.